For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity Terns plans to initiate a Phase 2 clinical trial ...

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 ...

Findings seen in people with type 2 diabetes. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in ...

The oral presentation "Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves ... to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root ...

potential once-monthly injectable GLP-1 receptor agonist. Participants treated with MET-097i saw a 7.5% drop in body weight ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

At the Max Planck Institute for Metabolism Research in Cologne, Jens Brüning is investigating the mechanisms through which ...